Advanced Prostate Cancer VL

The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares

Details
Andrey Soares joins Phillip Koo at the 13th International Uro-Oncology Conference in Sao Paulo, Brazil in a conversation on challenges and opportunities in the management of patients with high risk localized disease in Latin America as well as the ARASENS data in the metastatic castration sensitive prostate cancer setting. Dr, Soares elaborates on the work that still needs to be done in Brazil to...

Lessons Learned in the STAMPEDE Trial - Nicholas James

Details
Nicholas James joins Phillip Koo at the 13th International Uro-Oncology Conference in Brazil to discuss his presentation on the lessons learned from the STAMPEDE trial which shed insight into how we can improve the outcomes for men with metastatic prostate cancer. Professor James' lecture focuses on how Latin American countries can implement these lessons in conducting and setting up clinical tria...

Real-World Differences in Outcomes with First-Line Abiraterone Therapy Between African American and White Men with mCRPC - A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the JAMA Oncology article titled "Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone." The authors of this study aimed to investigate the differences in outcomes with first-line abiraterone therapy between African American and non-Hispanic White men with mCRPC in...

Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher

Details
Alicia Morgans is joined by Frank Schumacher to discuss the study results assessing the association of functional outcomes by decision-making approaches in men with metastatic prostate cancer. Dr. Schumacher and colleagues assessed the association of shared decision-making vs. physician- or patient-directed decisions and measurement of patient quality of life, including patient-reported functional...

Clinical Trials in Progress: PSMA-Based Radioligand, 177Lu-PNT2002 For Men With Metastatic Castration-Resistant Prostate Cancer - The SPLASH Study - Neil Fleshner

Details
Charles Ryan is joined by Neil Fleshner to discuss the multi-center, open-label, phase III SPLASH study evaluating the efficacy of 177Lu-PNT2002, a PSMA-based radioligand, for men with progressive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor axis-targeted (ARAT) therapy which is underway and accruing in many sites around the world. Biographies: Neil Fleshner, MD,...

Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne

Details
Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...

The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen

Details
Alicia Morgans and Silke Gillessen discuss the upcoming Advanced Prostate Cancer Consensus Conference scheduled as a hybrid meeting taking place on April 28 - 30, 2022 in Lugano, Switzerland. Clinical management of prostate cancer will be discussed including locally advanced high-risk prostate cancer, biochemical recurrence in prostate cancer, and metastatic hormone-sensitive patient treatments, w...

The Risk of Prostate Cancer in Men with Inherited Germline TP53 Variants - Kara Maxwell

Details
In this discussion between Kara Maxwell and Alicia Morgans, Dr Maxwell highlights the role of TP53 in cancer and understanding the Li-Fraumeni syndrome. Inherited germline TP53 pathogenic and likely pathogenic variants (gTP53) cause autosomal dominant multicancer predisposition including Li-Fraumeni syndrome and the work that Drs. Morgans and Maxwell discuss here sought to determine whether gTP53...

From the Stage to the Clinic and Back: Medicine and Burnout - Stuart H. Bloom

Details
Stuart Bloom, MD, a well-known Twin Cities oncologist, joins Charles Ryan, MD to highlight his work on physician burnout including his theatrical play “How to Avoid Burnout in 73 Minutes”. The play represents Dr. Bloom's path to becoming a physician. Dr. Bloom spent the first 30 years of his life as an actor and comedian, the next 31 as a physician. In this conversation, the pair discuss how he co...

Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio

Details
In this UroToday discussion Alicia Morgans and Ana Aparicio, discuss androgen indifferent prostate cancer and how to define those patients. The conversation kicks off with a discussion on the challenges of defining androgen indifferent prostate cancer patients. Dr. Aparicio then goes into a discussion on TP53, RB1, and PTEN alterations, and how they fit into her recent studies. Dr. Morgans and Dr....
email news signup